Shingles vaccine maker Curevo lands $110M, adds biotech vets to board
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round.
Curevo’s efforts target shingles, a painful condition caused by the reactivation of the chickenpox virus. They will challenge biotech giant GlaxoSmithKline’s Shingrix vaccine. Curevo will use the funding to advance Phase 2 trials of amezosvatein, its shingles vaccine built from a non-living component of the virus and a proprietary adjuvant.
With this new funding, Curevo bolsters the region’s reputation as a leader in innovative drug development.